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Background: C-reactive protein (CRP) is associated with increased risk of cardiovascular (CV) events; levels are reduced with statins. We 
investigated the prognostic value of serial CRP in post- ACS patients (pts) treated with statins.
Methods: CRP was measured at 30 days (30d) and 4 months (4M) following ACS in PROVE IT-TIMI 22, which randomized pts to intensive 
(atorvastatin 80 mg) or standard (pravastatin 40 mg) statin therapy for a mean of 2 yrs. Subjects missing CRP, w/ an event prior to 4M, or off 
study drug were excluded. Remaining pts were divided into 3 categories based on 30d and 4M CRP: neither level ≥2 mg/L, one level ≥2 mg/L, 
or both levels ≥2 mg/L, and a landmark analysis was done, starting at 4M. Cox proportional hazard models were adjusted for baseline clinical 
characteristics, statin therapy and 30d and 4M LDL-C.
Results: Of 2,668 pts, 44% had low CRPs (<2 mg/L) at 30d and 4M, 22% had CRP ≥2mg/L at either timepoint, and 34% had CRP ≥2 mg/L at 
both timepoints. The 2-yr rate of CV death/MI/stroke was 3.3%, 5.4%, and 7.4% in the three groups, respectively (Ptrend<0.001). This relationship 
persisted after multivariable adjustment (adj HR 1.71, 95% CI 1.08-2.73, P=0.02, comparing both vs. neither category). When stratified by treatment 
arm, there appeared to be a stronger gradient of risk in pts not on intensive statin therapy (Figure).
Conclusion: Persistently high CRP through 4M after ACS is an independent predictor of increased risk of CV death, MI or stroke. Intensive statin 
therapy may blunt this risk relationship.
